Estudio triton timi 38 pdf

A comparison of prasugrel cs747 and clopidogrel in acute. Jul 27, 2012 tritontimi 38 trial to assess improvement in therapeuticoutcomes by optimizing platelet inhibition with prasugrelthrombolysis in myocardial infarctions wiviott brigham and womens hospital, boston, maamerican heart association 2007 scientific sessions population and treatment. In triton timi 38, patients with moderate to highrisk acs 74% nsteacs undergoing pci treated with a p2y12 inhibitor x 14. In tritontimi 38, patients with moderate to highrisk acs 74% nsteacs. February 27, 2009 updated march 6, 2009 february 27, 2009 paris, france. In the principle timi 44 trial, the primary outcome was inhibition of platelet aggregation at 6 h assessed by lighttransmission aggregometry. Tritontimi 38 and principle timi 44 trials of prasugrel. Clopidogrel carga 300 mg y mantencion 75 mg diarios por 6 a 15 meses. In both studies, ppi use was at physicians discretion. Prasugrel versus clopidogrel in patients with acute coronary syndromes. Tritontimi 38 was designed as a collaboration between the timi study group, the sponsors daiichi sankyo and eli lilly and a steering committee of investigators see the appendix. Tritontimi 38 is a phase 3 comparison of prasugrel versus clopidogrel in patients with moderate to highrisk acs undergoing pci.

This analysis of the tritontimi 38 study showed a significant reduction in cardiovascular events in patients with acute st elevation myocardial infarction stemi, or highrisk heart attack treated with prasugrel compared with clopidogrel as early as 30 days 32 percent reduction, p0. In addition, it is the first largescale clinical events trial to assess whether a thienopyridine regimen that achieves a higher level of inhibition of platelet aggregation than the standard therapy. The tritontimi 38 trial randomized 608 moderate to highrisk acs patients scheduled for pci to receive prasugrel 60mg loading dose and then 10mg daily maintenance dose or clopidogrel 300. Triton timi 38 tested the hypothesis that an agent with. Mega jl1, close sl, wiviott sd, shen l, walker jr, simon t, antman em, braunwald e, sabatine ms.

In the principletimi 44 trial, the primary outcome was inhibition of platelet aggregation at 6 h assessed by lighttransmission aggregometry. Rates of timi major bleeding were higher with ticagrelor 2. Nov 25, 2004 the endpoint in this measure is a combination of cv death, nonfatal mi, or nonfatal stroke. Tritontimi 38 evaluated prasugrel compared with clopidogrel in patients with acute coronary syndromes. This analysis of the triton timi 38 study showed a significant reduction in cardiovascular events in patients with acute st elevation myocardial infarction stemi, or highrisk heart attack treated with prasugrel compared with clopidogrel as early as 30 days 32 percent reduction, p0. The endpoint in this measure is a combination of cv death, nonfatal mi, or nonfatal stroke. Genetic variants in abcb1 and cyp2c19 and cardiovascular. Improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel. Este estudio esta financiado por daiichi sankyo y eli lilly. The tritontimi 38 trial was supported by a research grant to the brigham and womens hospital from daiichi sankyo co. In the triton timi 38 trial, the primary endpoint was the composite of cardiovascular death, myocardial infarction, or stroke.

Mortality benefit with prasugrel in the tritontimi 38 coronary artery bypass grafting cohort. In the tritontimi 38 trial, the primary endpoint was the composite of cardiovascular death, myocardial infarction, or stroke. Tritontimi 38 aha 2007 orlando, florida disclosure statement. Comparison of ticagrelor with clopidogrel in patients with a. Tritontimi 38 is designed to compare prasugrel with clopidogrel in moderate to highrisk patients with acute coronary syndrome acs. Triton timi 38 is a phase 3 comparison of prasugrel versus clopidogrel in patients with moderate to highrisk acs undergoing pci. In tritontimi 38, patients with moderate to highrisk acs 74% nsteacs undergoing pci treated with a p2y12 inhibitor x 14. The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with kaplanmeier rates at 3 years of 7.

Longterm use of ticagrelor in patients with prior myocardial. Genetic variants in abcb1 and cyp2c19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the tritontimi 38 trial. Efficacy and safety of ticagrelor versus clopidogrel with. May 29, 2012 smith pk, goodnough lt, levy jh, et al. Prasugrel versus clopidogrel in patients with acute coronary. Ppt tritontimi 38 and principletimi 44 trials of prasugrel.

Tritontimi 38 study subgroup analysis by bleeding risk overall 60 kg. Oct 16, 2010 genetic variants in abcb1 and cyp2c19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the triton timi 38 trial. Analysis of cost effectiveness of prasugrel compared with. Tritontimi 38 trial to assess improvement in therapeuticoutcomes by optimizing platelet inhibition with prasugrelthrombolysis in myocardial infarctions wiviott brigham and womens hospital, boston, maamerican heart association 2007 scientific sessions population and treatment.

The tritontimi 38 trial was supported by a research grant to the brigham and womens hospital. Shuldiner et al, 2009 genomewide association study gwas. A free powerpoint ppt presentation displayed as a flash slide show on id. Evaluation of prasugrel compared with clopidogrel in patients. The data is presented by the study population, which is represented as follows.